Migliorini Adriana, Bader Erik, Lickert Heiko
Institute of Stem Cell Research, Helmholtz Zentrum München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany ; Institute of Diabetes and Regeneration Research, Helmholtz Zentrum München, Am Parkring 11, D-85748, Business Campus Garching, Germany.
Institute of Stem Cell Research, Helmholtz Zentrum München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany ; Institute of Diabetes and Regeneration Research, Helmholtz Zentrum München, Am Parkring 11, D-85748, Business Campus Garching, Germany ; Research Unit of Molecular Epidemiology Institute of Epidemiology II, Helmholtz Zentrum München, Ingolstädter Landstr. 1, D-85764 Neuherberg, Germany.
Mol Metab. 2014 Jan 22;3(3):268-74. doi: 10.1016/j.molmet.2014.01.010. eCollection 2014 Jun.
Insulin-dependent diabetes is a complex multifactorial disorder characterized by loss or dysfunction of β-cells resulting in failure of metabolic control. Even though type 1 and 2 diabetes differ in their pathogenesis, restoring β-cell function is the overarching goal for improved therapy of both diseases. This could be achieved either by cell-replacement therapy or by triggering intrinsic regenerative mechanisms of the pancreas. For type 1 diabetes, a combination of β-cell replacement and immunosuppressive therapy could be a curative treatment, whereas for type 2 diabetes enhancing endogenous mechanisms of β-cell regeneration might optimize blood glucose control. This review will briefly summarize recent efforts to allow β-cell regeneration where the most promising approaches are currently (1) increasing β-cell self-replication or neogenesis from ductal progenitors and (2) conversion of α-cells into β-cells.
胰岛素依赖型糖尿病是一种复杂的多因素疾病,其特征是β细胞丧失或功能障碍,导致代谢控制失败。尽管1型和2型糖尿病的发病机制不同,但恢复β细胞功能是改善这两种疾病治疗的首要目标。这可以通过细胞替代疗法或触发胰腺的内在再生机制来实现。对于1型糖尿病,β细胞替代和免疫抑制疗法相结合可能是一种治愈性治疗方法,而对于2型糖尿病,增强β细胞再生的内源性机制可能会优化血糖控制。本综述将简要总结目前在β细胞再生方面的最新研究成果,其中最有前景的方法目前有两种:(1)增加β细胞的自我复制或从导管祖细胞生成新的β细胞;(2)将α细胞转化为β细胞。